🔎 Trials Near Me

Home › Lymphoma › Ohio › Cleveland

Pag-aaral pangklinika para sa Lymphoma sa Cleveland, OH

Isang pag-aaral para sa Lymphoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Cleveland. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

Nagre-recruitPhase 1
  • University Hospitals Cleveland Medical Center, Cleveland
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07192471

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Nagre-recruitPhase 2
  • University Hospitals Cleveland Medical Center, Cleveland
1 Month – 17 Years · Lahat ng kasarian · Na-update Set 30, 2026 · NCT04570423

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Nagre-recruitPhase 2
  • Cleveland Clinic, Cleveland
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07015242

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Nagre-recruitPhase 2
  • The Cleveland Clinic Foundation, Cleveland
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07221500

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Nagre-recruitPhase 3
  • Research Site, Cleveland
Edad 18 hanggang 18 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07509151

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Nagre-recruitPhase 1/2
  • Cleveland Clinic, Cleveland
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Nagre-recruitPhase 1/2
  • Cleveland Clinic, Cleveland
Edad 12 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06678659

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Nagre-recruitPhase 3
  • Cleveland Clinical Taussig Cancer Center, Cleveland
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Nagre-recruitPhase 1
  • University Hospitals Cleveland Medical Center, Cleveland
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 8, 2026 · NCT07465835

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Nagre-recruitPhase 1
  • Cleveland Clinic, Cleveland
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Nagre-recruitPhase 1/2
  • Cleveland Clinic, Cleveland
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 16, 2026 · NCT03328078

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • Cleveland Clinic, Cleveland
Edad 40 pataas · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT05366881

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Nagre-recruitPhase 1
  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2025 · NCT06916767

Pag-aaral para sa Lymphoma sa ibang lungsod

Iba pang pag-aaral sa Cleveland

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.